15307-81-0

Basic information

• Product Name: Diclofenac potassium
• Synonyms: PotassiuM diclofenac;ProSorb;Diclofenic potassiuM;Benzeneaceticacid, 2-[(2,6-dichlorophenyl)aMino]-, potassiuM salt (1:1);potassium 2-(2-(2,6-dichlorophenylamino)phenyl)acetate;DICLOFENAC POTASSIUM;DICLOFENAC POTASSIUM SALT;2[(2,6-dichlorophenyl)amino]benzeneacetic acid potassium salt
• CAS NO: 15307-81-0
• Molecular Formula: C₁₄H₁₀Cl₂NO₂*K
• Molecular Weight: 334.24
• EINECS: 1312995-182-4
• Product Categories: Inhibitors;Active Pharmaceutical Ingredients;chiral;API's
• Mol File: 15307-81-0.mol
• Article Data: 1

Chemical Properties

• Melting Point: 300-330 °C
• Boiling Point: 412 °C at 760 mmHg
• Flash Point: 203 °C
• Appearance: /
• Vapor Pressure: 1.59E-07mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Sparingly soluble in water, freely soluble in methanol, soluble in ethanol (96 per cent), slightly soluble in acetone.
• CAS DataBase Reference: Diclofenac potassium(CAS DataBase Reference)
• NIST Chemistry Reference: Diclofenac potassium(15307-81-0)
• EPA Substance Registry System: Diclofenac potassium(15307-81-0)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-51/53
• Safety Statements: 61
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 15307-81-0(Hazardous Substances Data)

Usage

Description

Diclofenac potassium is the potassium salt of diclofenac, a nonsteroidal anti-inflammatory agent. It is a white or slightly yellowish, slightly hygroscopic, crystalline powder. It is used to reduce inflammation and as an analgesic to reduce pain in certain conditions. Diclofenac potassium exerts its action via inhibition of prostaglandin synthesis by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) with relative equipotency. However, recent studies have shown that the pharmacologic activity of diclofenac goes beyond COX inhibition, and includes multimodal and, in some instances, novel mechanisms of action (MOA). For example, research suggests diclofenac can inhibit the thromboxane-prostanoid receptor, affect arachidonic acid release and uptake, inhibit lipoxygenase enzymes, and activate the nitric oxide–cGMP antinociceptive pathway. Other novel MOAs may include the inhibition of substrate P, inhibition of peroxisome proliferator activated receptor gamma (PPARγ), blockage of acid-sensing ion channels, alteration of interleukin-6 production, and inhibition of N-methyl-D-aspartate (NMDA) receptor hyperalgesia.

Uses

Used in Pharmaceutical Industry:
Diclofenac potassium is used as a cyclo-oxygenase inhibitor for reducing inflammation and as an analgesic to reduce pain in certain conditions. It is particularly effective in treating dysmenorrhea, musculoskeletal complaints, dental pain, arthritis, actinic keratosis, joint pain, acute pain, and chronic pain caused by certain kinds of cancers.
Used in Pain Management:
Diclofenac potassium is used as an analgesic for managing pain associated with various conditions, such as musculoskeletal complaints, dental pain, arthritis, and joint pain.
Used in Inflammation Treatment:
Diclofenac potassium is used as an anti-inflammatory agent for treating inflammatory disorders, such as actinic keratosis and arthritis.
Used in Cancer Pain Management:
Diclofenac potassium is used as a pain reliever for managing chronic pain caused by certain kinds of cancers.
Brand Name:
Cataflam (Novartis) is a brand name for diclofenac potassium salt, which is a nonsteroidal anti-inflammatory compound and a cyclooxygenase (COX) inhibitor.

References

Brogden, R. N., et al. "Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin." Drugs 20.1 (1980): 24-48. Gan, Tong J. "Diclofenac: an update on its mechanism of action and safety profile." Current medical research and opinion 26.7 (2010): 1715-1731. Riihiluoma, P., E. Wuolijoki, and M. O. Pulkkinen. "Treatment of primary dysmenorrhea with diclofenac sodium." European Journal of Obstetrics & Gynecology and Reproductive Biology 12.3 (1981): 189-194.

InChI:InChI=1/C14H11Cl2NO2.K/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;/h1-7,17H,8H2,(H,18,19);/q;+1/p-1

Upstream product

• 15362-40-0 1-(2,6-dichlorophenyl)indolin-2-one 

Downstream Products

• 1246212-65-6 C₂₇H₁₇Cl₂N₄O₆^(1-)*K⁽¹⁺⁾ 
• 1246212-57-6 C₃₃H₂₁Cl₂N₄O₆^(1-)*K⁽¹⁺⁾ 
• 1246212-53-2 C₂₈H₁₉Cl₂N₄O₆^(1-)*K⁽¹⁺⁾ 
• 1246212-61-2 C₃₅H₂₆Cl₂N₅O₆^(1-)*K⁽¹⁺⁾ 
• 172494-87-0 2,6-dichloro-N-(o-tolyl)aniline 
• 95-57-8 2-monochlorophenol 
• 621-37-4 m-hydroxyphenylacetic acid 
• 95-48-7 ortho-cresol 

Related news

Effect of oral Diclofenac potassium (cas 15307-81-0) plus cervical lidocaine cream on pain perception during hysterosalpingography: A randomized, double-blind, placebo-controlled trial08/08/2019

ObjectiveThe current study aims to investigate the analgesic effect of combining oral diclofenac potassium and cervical lidocaine cream for alleviating pain during HSG.detailed

Clay nanotubes as a novel multifunctional excipient for the development of directly compressible Diclofenac potassium (cas 15307-81-0) tablets in a SeDeM driven QbD environment08/07/2019

Halloysite is a unique biocompatible aluminosilicate clay mineral with powder particles predominantly comprising of concentrically rolled nanotubular aggregates. Some recent studies have also contributed to its prospective case in oral drug delivery and dosage forms albeit with limited commercia...detailed

Oral Diclofenac potassium (cas 15307-81-0) Versus Hyoscine-N-Butyl Bromide in Reducing Pain Perception during Office Hysteroscopy: ARandomized Double-blind Placebo-controlled Trial08/06/2019

ABSTRACTStudy ObjectiveTo compare the efficacy of oral diclofenac potassium versus hyoscine-N-butyl bromide (HBB) in reducing pain perception in patients undergoing diagnostic office hysteroscopy (OH).detailed

Relevant articles and documents

PROCESS FOR THE PREPARATION OF DICLOFENAC EPOLAMINE

The present invention concerns a process for the preparation of the salt diclofenac epolamine comprising the following steps: a) reacting 1 -(2,6-dichlorophenyl)-2-indolinone with a base selected from sodium hydroxide or potassium hydroxide in an aqueous solvent, thus obtaining sodium or potassium diclofenac salt; b) dissolving the so obtained sodium or potassium diclofenac salt in a solvent- mixture comprising water and an organic solvent selected from the group consisting of ethyl acetate, methyl isobutyl ketone, toluene, isobutyl acetate, n-butyl acetate, n-propyl acetate, isopropyl acetate; c) adding a strong acid to give diclofenac acid and removing the water phase; d) anhydrifying the remaining organic solvent phase; and e) adding 1-(2-hydroxyethyl)-pyrrolidine.